BioInno

Tempus Fugit

In northern hemispheres, October heralds the onset of autumn and we are reminded that its cool breezes will soon blow wintry as 1996 draws to a close. Tempus fugit! The swift passage of time also reminds us that the first volume of The Oncologist will soon conclude with its sixth issue in December.

However, before 1996 becomes history, let’s pause and reflect on the pledges we made to our readership at the beginning of the year. The Founding Editors conceived the Journal to provide authoritative, topical, innovative articles in an attractive format for a very special reader: the busy, practicing physician who cares for cancer patients.

STA-21

2626-250
EUR 185

Isovaleryl-Phe-Nle-Sta-Ala-Sta-OH

H-5435.0001 1.0mg
EUR 357
Description: Sum Formula: C39H65N5O9; CAS# [98092-14-9]

Isovaleryl-Phe-Nle-Sta-Ala-Sta-OH

H-5435.0005 5.0mg
EUR 1336
Description: Sum Formula: C39H65N5O9; CAS# [98092-14-9]

Ral Activation Assay Kit, Trial Size

STA-408-T 5 assays
EUR 403
Description: Our Ral Activation Assay uses visible agarose beads to selectively precipitate the active form of Ral protein. The precipitated small GTPase is then detected by Western blot using a Ral-specific antibody included in the kit.

Ganetespib (STA-9090)

A4385-10 10 mg
EUR 267
Description: Ganetespib (also known as STA-9090), 5-[2,4-dihydroxy-5-(1 methylethyl)phenyl]-2,4 dihydro-4-(1-methyl-1H indol-5 yl)-3H-1,2,4 triazole-3-one, is a potent small-molecule inhibitor of heat shock protein 90 (Hsp90), which binds to the ATP pocket in the N-terminus of Hsp90.

Ganetespib (STA-9090)

A4385-200 200 mg
EUR 1964
Description: Ganetespib (also known as STA-9090), 5-[2,4-dihydroxy-5-(1 methylethyl)phenyl]-2,4 dihydro-4-(1-methyl-1H indol-5 yl)-3H-1,2,4 triazole-3-one, is a potent small-molecule inhibitor of heat shock protein 90 (Hsp90), which binds to the ATP pocket in the N-terminus of Hsp90.

Ganetespib (STA-9090)

A4385-5 5 mg
EUR 206
Description: Ganetespib (also known as STA-9090), 5-[2,4-dihydroxy-5-(1 methylethyl)phenyl]-2,4 dihydro-4-(1-methyl-1H indol-5 yl)-3H-1,2,4 triazole-3-one, is a potent small-molecule inhibitor of heat shock protein 90 (Hsp90), which binds to the ATP pocket in the N-terminus of Hsp90.

Ganetespib (STA-9090)

A4385-5.1 10 mM (in 1mL DMSO)
EUR 224
Description: Ganetespib (also known as STA-9090), 5-[2,4-dihydroxy-5-(1 methylethyl)phenyl]-2,4 dihydro-4-(1-methyl-1H indol-5 yl)-3H-1,2,4 triazole-3-one, is a potent small-molecule inhibitor of heat shock protein 90 (Hsp90), which binds to the ATP pocket in the N-terminus of Hsp90.

Ganetespib (STA-9090)

A4385-50 50 mg
EUR 688
Description: Ganetespib (also known as STA-9090), 5-[2,4-dihydroxy-5-(1 methylethyl)phenyl]-2,4 dihydro-4-(1-methyl-1H indol-5 yl)-3H-1,2,4 triazole-3-one, is a potent small-molecule inhibitor of heat shock protein 90 (Hsp90), which binds to the ATP pocket in the N-terminus of Hsp90.

Ganetespib (STA-9090)

A4385-S Evaluation Sample
EUR 81
Description: Ganetespib (also known as STA-9090), 5-[2,4-dihydroxy-5-(1 methylethyl)phenyl]-2,4 dihydro-4-(1-methyl-1H indol-5 yl)-3H-1,2,4 triazole-3-one, is a potent small-molecule inhibitor of heat shock protein 90 (Hsp90), which binds to the ATP pocket in the N-terminus of Hsp90.

Elesclomol (STA-4783)

A4386-10 10 mg
EUR 311
Description: Elesclomol (also known as STA-4783), originally identified in a cell-based phenotypic screen for proapoptotic activity, is a novel small-molecule that potently induces apoptosis of cancer cells through the rapid generation of reactive oxygen species (ROS).

Elesclomol (STA-4783)

A4386-200 200 mg
EUR 2071
Description: Elesclomol (also known as STA-4783), originally identified in a cell-based phenotypic screen for proapoptotic activity, is a novel small-molecule that potently induces apoptosis of cancer cells through the rapid generation of reactive oxygen species (ROS).

Elesclomol (STA-4783)

A4386-5 5 mg
EUR 187
Description: Elesclomol (also known as STA-4783), originally identified in a cell-based phenotypic screen for proapoptotic activity, is a novel small-molecule that potently induces apoptosis of cancer cells through the rapid generation of reactive oxygen species (ROS).

Elesclomol (STA-4783)

A4386-5.1 10 mM (in 1mL DMSO)
EUR 200
Description: Elesclomol (also known as STA-4783), originally identified in a cell-based phenotypic screen for proapoptotic activity, is a novel small-molecule that potently induces apoptosis of cancer cells through the rapid generation of reactive oxygen species (ROS).

Elesclomol (STA-4783)

A4386-50 50 mg
EUR 843
Description: Elesclomol (also known as STA-4783), originally identified in a cell-based phenotypic screen for proapoptotic activity, is a novel small-molecule that potently induces apoptosis of cancer cells through the rapid generation of reactive oxygen species (ROS).

Elesclomol (STA-4783)

B1815-25
EUR 637

Elesclomol (STA-4783)

B1815-5
EUR 196

Ganetespib (STA-9090)

9459-25
EUR 588

Ganetespib (STA-9090)

9459-5
EUR 185

RTA-408

HY-12212 100mg
EUR 796

RTA 408

B2860-25
EUR 544

RTA 408

B2860-5
EUR 175

HBS w/Phenol Red, 500 ml

408 500 ml
EUR 72

Ac-Pepstatin [Ac-Val-Val-Sta-Ala-Sta (MW: 471.56)]

SP-86490-10 10mg
EUR 225

Omaveloxolone (RTA-408)

B3576-25 25 mg
EUR 531
Description: Omaveloxolone (RTA-408)

Omaveloxolone (RTA-408)

B3576-5 5 mg
EUR 206
Description: Omaveloxolone (RTA-408)

Isovaleryl-Val-Val-Sta-OEt

H-6680.0001 1.0mg
EUR 357
Description: Sum Formula: C25H47N3O6; CAS# [120849-36-7]

Isovaleryl-Val-Val-Sta-OEt

H-6680.0005 5.0mg
EUR 1336
Description: Sum Formula: C25H47N3O6; CAS# [120849-36-7]

Tau Peptide (379-408)

H-8172.0500 0.5mg
EUR 300
Description: Sum Formula: C140H228N44O46; CAS# [1246357-53-8] net

Tau Peptide (379-408)

H-8172.1000 1.0mg
EUR 495
Description: Sum Formula: C140H228N44O46; CAS# [1246357-53-8] net

DNase I (MBG)

408-050 50 mg
EUR 72

DNase I (MBG)

408-1000 1000 mg
EUR 583

DNase I (MBG)

408-250 250 mg
EUR 206

CRE-2A-GFP (CMV-Neo), Ultra titer lentivirus

ULVP-408 1 x109 IFU/ml x 50 ul
EUR 1065
Description: Pre-made lentiviral particles bicistronically express individual nuclear permeable CRE recombinase and the GFP marker under the same suCMV promoter. A Neomycin marker was expressed under RSV promoter. Virus concentrated and buffer changed into PBS solution.

Recombinant (E.Coli, His-tag) Human Secreted Phospholipase A2-IID

RP-408 10 ug
EUR 286

IFNAR 2 Recombinant Protein

96-408 1 mg
EUR 2327.75
Description: Interferon alpha/beta receptor 2 (IFNAR2) is also known as IFN-alpha binding protein, IFN-alpha/beta receptor 2, Type I interferon receptor 2, IFNABR and IFNARB, which is a single-pass type I membrane protein and belongs to the type II cytokine receptor family. IFNAR2 can associate with IFNAR1 to form the type I interferon receptor. IFNAR2 is a receptor for interferons alpha and beta.IFNAR2 involves in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 of IFNAR2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 of IFNAR2 is a potent inhibitor of type I IFN receptor activity.Genetic variations in IFNAR2 influence susceptibility to hepatitis B virus (HBV) infection.

SARS-CoV-2 (COVID-19) NSP10 Recombinant Protein

10-408 0.1 mg
EUR 542.75
Description: Nsp10 have shown that it is a 15-kDa protein of unknown function that has been shown to interact with itself, nsp1, and nsp7. It colocalizes with N to sites of viral replication and is essential for replication. It plays a pivotal role in viral transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16 2'-O-methyltransferase activities. Therefore plays an essential role in viral mRNAs cap methylation. Nsp10 is a critical regulator of coronavirus RNA synthesis and may play an important role in polyprotein processing.

ICOS / CD278 (C136S, C137S) Recombinant Protein

11-408 0.1 mg
EUR 595.25
Description: Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

CD134 [OX40] Recombinant Protein

90-408 25 ug
EUR 490.25
Description: CD134 (OX40) is a T cell activation antigen structurally belonging to a lymphocyte-specific subgroup of the nerve growth factor and tumor necrosis factor receptor superfamily, which also includes the T cell antigen CD27, B cell antigen CD40, FAS antigen and the T cell activation antigen 4-1BB. The human CD134 protein is expressed only on activated CD4+ T blasts, and its ligand has been identified as gp34. Interactions between CD134 and its ligand in vivo are necessary for the differentiation of activated B cells into highly immunoglobulin-producing cells, however not involved in other pathways of antigen-driven differentiation of B cells such as development of memory cells in the germinal centers. In addition, the CD134 and gp34 system directly mediate adhesion of activated T cells to vascular endothelial cells, and contribute to growth stimulation of the virus-infected T cells.

Chitinase-3-Like Protein 1 Recombinant Protein

91-408 0.05 mg
EUR 464
Description: Chitinase-3-Like Protein 1 (CHI3L1) belongs to the glycosyl hydrolase 18 family. CHI3L1 is expressed in activated macrophages, articular chondrocytes, synovial cells as well as in liver. It lacks chitinase activity and is secreted by activated macrophages, chondrocytes, neutrophils and synovial cells. CHI3L1 is thought to play a role in defense against pathogens, or in tissue remodeling, and in the capacity of cells to respond to and cope with changes in their environment. In addition, CHI3L1 is associated with susceptibility to asthma-related traits type 7 (ASRT7) which assessed by methacholine challenge test, serum IgE levels, atopy, and atopic dermatitis.

Nectin-2 Recombinant Protein

92-408 0.05 mg
EUR 364.25
Description: Nectin-2( CD112) is a member of the nectin family, which contains two Ig-like C2-type domains and one Ig-like V-type domain in the extracellular region. Nectins are type I transmembrane glycoproteins that are calcium-independent immunoglobulin (Ig)-like cell adhesion molecules (CAMs). Nectin2 is widely expressed in human tissues including brain, spinal cord, spleen, kidney, heart and liver. It can form trans-heterodimers with PVRL3/nectin-3 and interacts with CD226. Mutations of alleles of the murine CD112 gene can result in conditions such as morphologically aberrant spermatozoa. It may function in allergic reactions, and accordingly may used as a novel target for anti-allergic therapy.

for Heat Stable Enterotoxin a (STa)ELISA kit

SEO805Ge-10x96wellstestplate 10x96-wells test plate
EUR 5386
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of for Heat Stable Enterotoxin a (STa) in Biological agents.

for Heat Stable Enterotoxin a (STa)ELISA kit

SEO805Ge-1x48wellstestplate 1x48-wells test plate
EUR 531.2
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of for Heat Stable Enterotoxin a (STa) in Biological agents.

for Heat Stable Enterotoxin a (STa)ELISA kit

SEO805Ge-1x96wellstestplate 1x96-wells test plate
EUR 716
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of for Heat Stable Enterotoxin a (STa) in Biological agents.

for Heat Stable Enterotoxin a (STa)ELISA kit

SEO805Ge-5x96wellstestplate 5x96-wells test plate
EUR 2922
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of for Heat Stable Enterotoxin a (STa) in Biological agents.

ELISA Kit for Heat Stable Enterotoxin a (STa)

4-SEO805Ge
  • EUR 5437.00
  • EUR 2873.00
  • EUR 717.00
  • 10 plates of 96 wells
  • 5 plates of 96 wells
  • 1 plate of 96 wells
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Heat Stable Enterotoxin a (STa) in samples from Biological agents with no significant corss-reactivity with analogues from other species.

Zinc Finger Protein 408 (ZNF408) Antibody

20-abx006171
  • EUR 411.00
  • EUR 592.00
  • EUR 182.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Zinc Finger Protein 408 (ZNF408) Antibody

abx029238-400ul 400 ul
EUR 523

Zinc Finger Protein 408 (ZNF408) Antibody

abx029238-80l 80 µl
EUR 286

Zinc Finger Protein 408 (ZNF408) Antibody

20-abx313196
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Polyclonal XPO1 / CRM1 Antibody (aa390-408)

AMM08530G 0.05mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human XPO1 / CRM1 (aa390-408). This antibody is tested and proven to work in the following applications:

Porcine Signal transducer and activator of transcription 5B, STA

ELI-39535p 96 Tests
EUR 928

Porcine Signal transducer and activator of transcription 5A, STA

ELI-05635p 96 Tests
EUR 928

Zinc Finger Protein 408 (ZNF408) Antibody (HRP)

20-abx313197
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Zinc Finger Protein 408 (ZNF408) Antibody (FITC)

20-abx313198
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Zinc Finger Protein 408 (ZNF408) Antibody (Biotin)

20-abx313199
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Recombinant Salmonella astC Protein (aa 1-408)

VAng-Wyb1001-1mgEcoli 1 mg (E. coli)
EUR 5023
Description: Salmonella agona (strain SL483) Succinylornithine transaminase, recombinant protein.

Recombinant Salmonella astC Protein (aa 1-408)

VAng-Wyb1001-500gEcoli 500 µg (E. coli)
EUR 3396
Description: Salmonella agona (strain SL483) Succinylornithine transaminase, recombinant protein.

Recombinant Salmonella astC Protein (aa 1-408)

VAng-Wyb1001-50gEcoli 50 µg (E. coli)
EUR 2308
Description: Salmonella agona (strain SL483) Succinylornithine transaminase, recombinant protein.

EBV NA1 (aa 1 - 90, 408 - 498) [GST]

DAG2362 100 µg
EUR 724

Recombinant Shigella Dysenteriae pepT Protein (aa 1-408)

VAng-Lsx07053-1mgEcoli 1 mg (E. coli)
EUR 4793
Description: Shigella Dysenteriae serotype 1 (strain Sd197) Peptidase T, recombinant protein.

Recombinant Shigella Dysenteriae pepT Protein (aa 1-408)

VAng-Lsx07053-500gEcoli 500 µg (E. coli)
EUR 3390
Description: Shigella Dysenteriae serotype 1 (strain Sd197) Peptidase T, recombinant protein.

Recombinant Shigella Dysenteriae pepT Protein (aa 1-408)

VAng-Lsx07053-50gEcoli 50 µg (E. coli)
EUR 2305
Description: Shigella Dysenteriae serotype 1 (strain Sd197) Peptidase T, recombinant protein.

Recombinant Shigella Flexneri pepT Protein (aa 1-408)

VAng-Lsx08016-1mgEcoli 1 mg (E. coli)
EUR 5095
Description: Shigella Flexneri Peptidase T, recombinant protein.

Recombinant Shigella Flexneri pepT Protein (aa 1-408)

VAng-Lsx08016-500gEcoli 500 µg (E. coli)
EUR 3390
Description: Shigella Flexneri Peptidase T, recombinant protein.

Recombinant Shigella Flexneri pepT Protein (aa 1-408)

VAng-Lsx08016-50gEcoli 50 µg (E. coli)
EUR 2305
Description: Shigella Flexneri Peptidase T, recombinant protein.

Recombinant Shigella Sonnei pepT Protein (aa 1-408)

VAng-Lsx09989-1mgEcoli 1 mg (E. coli)
EUR 5095
Description: Shigella Sonnei (strain Ss046) Peptidase T, recombinant protein.

Recombinant Shigella Sonnei pepT Protein (aa 1-408)

VAng-Lsx09989-500gEcoli 500 µg (E. coli)
EUR 3390
Description: Shigella Sonnei (strain Ss046) Peptidase T, recombinant protein.

Recombinant Shigella Sonnei pepT Protein (aa 1-408)

VAng-Lsx09989-50gEcoli 50 µg (E. coli)
EUR 2305
Description: Shigella Sonnei (strain Ss046) Peptidase T, recombinant protein.

Recombinant Borrelia Duttonii ackA Protein (aa 1-408)

VAng-Lsx1925-1mgEcoli 1 mg (E. coli)
EUR 5023
Description: Borrelia Duttonii Acetate kinase, recombinant protein.

Recombinant Borrelia Duttonii ackA Protein (aa 1-408)

VAng-Lsx1925-500gEcoli 500 µg (E. coli)
EUR 3396
Description: Borrelia Duttonii Acetate kinase, recombinant protein.

Recombinant Borrelia Duttonii ackA Protein (aa 1-408)

VAng-Lsx1925-50gEcoli 50 µg (E. coli)
EUR 2308
Description: Borrelia Duttonii Acetate kinase, recombinant protein.

Recombinant Borrelia Hermsii ackA Protein (aa 1-408)

VAng-Lsx2236-1mgEcoli 1 mg (E. coli)
EUR 5023
Description: Borrelia Hermsii Acetate kinase, recombinant protein.

Recombinant Borrelia Hermsii ackA Protein (aa 1-408)

VAng-Lsx2236-500gEcoli 500 µg (E. coli)
EUR 3396
Description: Borrelia Hermsii Acetate kinase, recombinant protein.

Recombinant Borrelia Hermsii ackA Protein (aa 1-408)

VAng-Lsx2236-50gEcoli 50 µg (E. coli)
EUR 2308
Description: Borrelia Hermsii Acetate kinase, recombinant protein.

Recombinant Borrelia Recurrentis ackA Protein (aa 1-408)

VAng-Lsx2356-1mgEcoli 1 mg (E. coli)
EUR 5023
Description: Borrelia Recurrentis Acetate kinase, recombinant protein.

Recombinant Borrelia Recurrentis ackA Protein (aa 1-408)

VAng-Lsx2356-500gEcoli 500 µg (E. coli)
EUR 3396
Description: Borrelia Recurrentis Acetate kinase, recombinant protein.

Recombinant Borrelia Recurrentis ackA Protein (aa 1-408)

VAng-Lsx2356-50gEcoli 50 µg (E. coli)
EUR 2308
Description: Borrelia Recurrentis Acetate kinase, recombinant protein.

Recombinant Escherichia coli rtcB Protein (aa 1-408)

VAng-Lsx3109-1mgEcoli 1 mg (E. coli)
EUR 717
Description: Escherichia coli RNA-splicing ligase RtcB, recombinant protein.

Recombinant Escherichia coli rtcB Protein (aa 1-408)

VAng-Lsx3109-500gEcoli 500 µg (E. coli)
EUR 495
Description: Escherichia coli RNA-splicing ligase RtcB, recombinant protein.

Recombinant Escherichia coli rtcB Protein (aa 1-408)

VAng-Lsx3109-50gEcoli 50 µg (E. coli)
EUR 354
Description: Escherichia coli RNA-splicing ligase RtcB, recombinant protein.

Recombinant Shigella Boydii dsdA Protein (aa 1-408)

VAng-Lsx09090-1mgEcoli 1 mg (E. coli)
EUR 5095
Description: Shigella Boydii serotype 4 (strain Sb227) D-serine dehydratase, recombinant protein.

Recombinant Shigella Boydii dsdA Protein (aa 1-408)

VAng-Lsx09090-500gEcoli 500 µg (E. coli)
EUR 3390
Description: Shigella Boydii serotype 4 (strain Sb227) D-serine dehydratase, recombinant protein.

Recombinant Shigella Boydii dsdA Protein (aa 1-408)

VAng-Lsx09090-50gEcoli 50 µg (E. coli)
EUR 2305
Description: Shigella Boydii serotype 4 (strain Sb227) D-serine dehydratase, recombinant protein.

Recombinant Mycoplasma Pneumoniae csd Protein (aa 1-408)

VAng-Lsx04703-1mgEcoli 1 mg (E. coli)
EUR 4793
Description: Mycoplasma Pneumoniae (strain ATCC 29342 / M129) Probable cysteine desulfurase, recombinant protein.

Recombinant Mycoplasma Pneumoniae csd Protein (aa 1-408)

VAng-Lsx04703-50gEcoli 50 µg (E. coli)
EUR 2305
Description: Mycoplasma Pneumoniae (strain ATCC 29342 / M129) Probable cysteine desulfurase, recombinant protein.

Recombinant Mycoplasma Pneumoniae csd Protein (aa 1-408)

VAng-Lsx04703-500gEcoli 500 µg (E. coli)
EUR 3390
Description: Mycoplasma Pneumoniae (strain ATCC 29342 / M129) Probable cysteine desulfurase, recombinant protein.

Recombinant Mycoplasma Capricolum ecfA2 Protein (aa 1-408)

VAng-Lsx06183-1mgEcoli 1 mg (E. coli)
EUR 4793
Description: Mycoplasma Capricolum subsp. capricolum (strain California kid / ATCC 27343 / NCTC 10154) Energy-coupling factor transporter ATP-binding protein EcfA 2, recombinant protein.

Recombinant Mycoplasma Capricolum ecfA2 Protein (aa 1-408)

VAng-Lsx06183-500gEcoli 500 µg (E. coli)
EUR 3390
Description: Mycoplasma Capricolum subsp. capricolum (strain California kid / ATCC 27343 / NCTC 10154) Energy-coupling factor transporter ATP-binding protein EcfA 2, recombinant protein.

Recombinant Mycoplasma Capricolum ecfA2 Protein (aa 1-408)

VAng-Lsx06183-50gEcoli 50 µg (E. coli)
EUR 2305
Description: Mycoplasma Capricolum subsp. capricolum (strain California kid / ATCC 27343 / NCTC 10154) Energy-coupling factor transporter ATP-binding protein EcfA 2, recombinant protein.

Recombinant Mycobacterium Tuberculosis eis Protein (aa 1-408)

VAng-Yyj0040-50gEcoli 50 µg (E. coli)
EUR 2308
Description: Mycobacterium Tuberculosis Enhanced intracellular survival protein (eis), recombinant protein.

Recombinant Mycobacterium Avium murG Protein(aa 1-408)

VAng-Yyj1344-50gEcoli 50 µg (E. coli)
EUR 2308
Description: Mycobacterium Avium (strain 104) UDP-N-acetylglucosamine--N-acetylmuramyl- (pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase (murG), recombinant protein.

Recombinant Mycobacterium Paratuberculosis murG Protein(aa 1-408)

VAng-Yyj1670-50gEcoli 50 µg (E. coli)
EUR 2308
Description: Mycobacterium Paratuberculosis UDP-N-acetylglucosamine--N-acetylmuramyl- (pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase (murG), recombinant protein.

Recombinant Mycobacterium Avium murG Protein (aa 1-408)

VAng-Yyj2672-1mgEcoli 1 mg (E. coli)
EUR 4789
Description: Mycobacterium Avium (strain 104) UDP-N-acetylglucosamine--N-acetylmuramyl- (pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase (murG), recombinant protein.

Recombinant Mycobacterium Avium murG Protein (aa 1-408)

VAng-Yyj2672-500gEcoli 500 µg (E. coli)
EUR 3396
Description: Mycobacterium Avium (strain 104) UDP-N-acetylglucosamine--N-acetylmuramyl- (pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase (murG), recombinant protein.

Recombinant Mycobacterium Avium murG Protein (aa 1-408)

VAng-Yyj2672-50gEcoli 50 µg (E. coli)
EUR 2308
Description: Mycobacterium Avium (strain 104) UDP-N-acetylglucosamine--N-acetylmuramyl- (pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase (murG), recombinant protein.

Our commitment is to critically review and publish papers designed to interpret the vast amounts of data available to physicians. As the famed radiotherapist and Founding Editor, Eli Glatstein, summarized, “The Oncologist emphasizes the interpretation rather than the data.” The Oncologist to date has published more than forty manuscripts from international authorities. The inaugural issue featured, among other highly acclaimed papers, “Locally Advanced Breast Cancer,” by Valero, Buzdar and Hortobagyi, and David Kuter’s “Thrombopoietin:

Biology and Clinical Applications.” Fidias, Chabner and Grossbard contributed “Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders” in the next issue, and Pavletic and Armitage proffered an update on “Bone Marrow Transplantation for Cancer.” Issue 4 highlighted Jemi Olak and Arthur Ng’s “Diagnosis and Management of Early-Stage Non-Small Cell Lung Cancer,” as well as “Multimodality Therapy for Esophageal Cancer” by Siewert, Stein and Fink. In this current issue, “Dose Intensity of Chemotherapy for Childhood Cancers,” by Smith, Abrams, Trimble and Ungerleider, and “Surgical Sphincter Preservation in Rectal Cancer” by Peter M.

Schlag present contemporary and authoritative views of two important clinical topics which also document the Journal’s intent to discuss both adult and pediatric cancer care. Our Meet The Professor section is fast becoming a popular feature which attracts comments from readers and responses from the author professor.

We call your attention to Professor Barrie R. Cassileth’s fascinating article, “Alternative and Complementary Cancer Treatments,” and her commentary in this issue.

The Physician Education section has presented hematopoiesis through informative and beautifully illustrated papers with texts by distinguished hematologists and molecular biologists. In this issue, we feature the first Patient Care section, From The Bethesda Post, wherein clinical trials and experimental treatments are announced. In cooperation with The Cancer Letter, The Oncologist News Bulletin presents late-breaking news pertinent to the world’s cancer care community.

With this issue, we have instituted an addition to this section, featuring information from Memorial Sloan-Kettering Cancer Center on a study involving Ashkenazi Jewish women. We urge cancer centers, pharmaceutical and biotechnology companies to avail themselves of this section by sending our editorial office your newsworthy reports. We hope that our readers are benefiting from the Journal and enjoying the art which has graced it. In order to assess how well we are fulfilling our pledges to our readership, we need to hear from you.

Tell us how we can make The Oncologist more relevant to your medical practice. We promise to share your comments with our Editorial Board to further enhance the Journal. In so doing, we will draw closer to fulfilling our pledge to you, our readers.

Scroll To Top